相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting MDM2 for novel molecular therapy: Beyond oncology
Wei Wang et al.
MEDICINAL RESEARCH REVIEWS (2020)
Incidence and patterns of malignancies in a multi-ethnic cohort of rheumatoid arthritis patients
Xin Rong Lim et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2019)
Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes
G. J. Ortiz et al.
ONCOGENE (2018)
The ID genotype of MDM2 40 bp insertion/deletion polymorphism was associated with lower risk of SLE
Saeedeh Salimi et al.
POSTGRADUATE MEDICAL JOURNAL (2017)
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
Liv B. Gansmo et al.
BMC CANCER (2017)
MDM2 promotes rheumatoid arthritis via activation of MAPK and NF-kappa B
Lin Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer
Liv B. Gansmo et al.
TUMOR BIOLOGY (2016)
Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate
Liv B. Gansmo et al.
ONCOTARGET (2016)
MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer
Reham Helwa et al.
SCIENTIFIC REPORTS (2016)
A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer
Shane Stegeman et al.
ENDOCRINE-RELATED CANCER (2015)
MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk
Liv B. Gansmo et al.
CANCER MEDICINE (2015)
Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon
Liv B. Gansmo et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2015)
Role of p53 in Systemic Autoimmune Diseases
Hiroaki Takatori et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2014)
Genetics of rheumatoid arthritis contributes to biology and drug discovery
Yukinori Okada et al.
NATURE (2014)
Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649)
Stian Knappskog et al.
ONCOTARGET (2014)
p53 Controls Autoimmune Arthritis via STAT-Mediated Regulation of the Th17 Cell/Treg Cell Balance in Mice
Jin-Sil Park et al.
ARTHRITIS AND RHEUMATISM (2013)
Different apoptotic responses of RA synoviocytes depending on different genotypes of the mdm2 SNP T309G
Kristina Heyne et al.
APOPTOSIS (2012)
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer
Stian Knappskog et al.
EUROPEAN JOURNAL OF CANCER (2012)
A 40-bp insertion/deletion polymorphism in the constitutive promoter of MDM2 confers risk for hepatocellular carcinoma in a Chinese population
Dong Dong et al.
GENE (2012)
Associations between the p53 codon 72 polymorphisms and susceptibility to systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis
Y. H. Lee et al.
LUPUS (2012)
The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians
Stian Knappskog et al.
CANCER CELL (2011)
MdmX Protein Is Essential for Mdm2 Protein-mediated p53 Polyubiquitination
Xinjiang Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Mdm2 Promotes Systemic Lupus Erythematosus and Lupus Nephritis
Ramanjaneyulu Allam et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis
Konstantinos P. Economopoulos et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity
Jessika Wynendaele et al.
CANCER RESEARCH (2010)
Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-α blocking agents
E. H. Halvorsen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
p53 polymorphisms: cancer implications
Catherine Whibley et al.
NATURE REVIEWS CANCER (2009)
Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression
E. A. Haavardsholm et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Cohort Profile: Cohort of Norway (CONOR)
Oyvind Naess et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2008)
High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis:: results from a 10-year longitudinal study
S. W. Syversen et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility:: Evidence from 21 case-control studies
Zhibin Hu et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
Mutations and polymorphisms of the p21B transcript in breast cancer
Stian Knappskog et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Regulating the p53 pathway:: in vitro hypotheses, in vivo veritas
Franck Toledo et al.
NATURE REVIEWS CANCER (2006)
p53 polymorphic variants at codon 72 exert different effects on cell cycle progression
D Pim et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
GL Bond et al.
CELL (2004)
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53
LK Linares et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The codon 72 polymorphic variants of p53 have markedly different apoptotic potential
P Dumont et al.
NATURE GENETICS (2003)
分享论文
